医学
胶质瘤
临床实习
工作队
磁共振成像
切除术
放射治疗
任务(项目管理)
梅德林
星形细胞瘤
药物治疗
循证医学
外科切除术
医学物理学
放射外科
生活质量(医疗保健)
总体生存率
病态的
结果(博弈论)
外科
重症监护医学
胶质母细胞瘤
放射科
作者
Roland Goldbrunner,Nikolaos Foroglou,Francesco Signorelli,Philippe Schucht,Asgeir Store Jakola,Giuseppe Minniti,Radosław Rola,Mirjam Renovanz,Matthias Preusser,Julia Furtner,Rachel Grossman,Christian Mawrin,Andreas K. Demetriades,Michael Weller,Matthias Simon
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2025-09-13
卷期号:28 (1): 38-54
被引量:5
标识
DOI:10.1093/neuonc/noaf217
摘要
Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence employed toward personalized treatment decisions is still moderate. Therefore, a joint task force was created by the European Association for Neurosurgical Societies (EANS) and the European Association of Neuro-Oncology (EANO) in order to provide interdisciplinary guidance on the extent of resection (EOR) in glioma surgery. This task force assessed the data on the EOR in gliomas, evaluated the level of evidence, and composed recommendations. The EOR is determined routinely by postoperative magnetic resonance imaging. Since EOR may be associated with survival and may have an impact on epilepsy, neurocognition, quality of life, neurological status, and also on planning of radiation and pharmacotherapy (evidence classes I-IV), recommendations of different levels can be made for the resection of newly diagnosed glioblastomas (level A), recurrent glioblastomas (level C), newly diagnosed (level B) and recurrent (good practice point) IDH mutant gliomas, ependymomas in children (level B) and adults (good practice point) as well as World Health Organization CNS grade 1 tumors (good practice point). We hereby report the outcome of this collaborative effort by the joint task force between EANS and EANO.
科研通智能强力驱动
Strongly Powered by AbleSci AI